A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.

• Status: Recruiting
• Trial end date: 2024-02-26

Summary

This is a modular Phase I/IIa, open-label, multi-centre, study of AZD7648 administered orally, either as a monotherapy, or in combination with either cytotoxic chemotherapies or novel anti-cancer agents in participants with advanced malignancies.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Parexel
• Treatments: Antineoplastic Agents; AZD7648; Doxorubicin; Liposomal doxorubicin; Olaparib